• All News
• 2021
• 2020
• 2019
• 2017
• 2016
• 2015
• 2014

Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)

Aug 11, 2014

Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)

Jun 30, 2014

Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)

Jun 11, 2014

Xenetic Biosciences Strengthens Technology Patent Portfolio

Jun 9, 2014

Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference

May 29, 2014

Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update

May 21, 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity

May 12, 2014

Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors

May 5, 2014

Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update

Apr 16, 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

Apr 7, 2014

• « Previous
• 1...
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• Next »